A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Cisplatin in Subjects with Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)

Diseases and Conditions Researched

Lung

What is the purpose of this trial?

The study consists of a Phase1b lead-in portion to determine the MTD of OMP-59R5 in combination with EP for 6 cycles followed a Phase 2, multicenter, randomized, placebo-controlled portion comparing the efficacy and safety of OMP-59R5 in combination with EP for 6 cycles followed by single agent OMP-59R5 relative to EP alone for 6 cycles in subjects receiving first-line therapy for extensive stage small cell lung cancer.


Participation Guidelines

Age: Any

Click here for detailed participation information for this trial.

Sponsor: OncoMed Pharmaceuticals
Dates:
Last Updated:
Study HIC#: 1311013077